此外，香港证监会于上季通过签订多份谅解备忘录加强与成熟及新兴海外市场的联系。香港证监会与爱 尔兰中央银行于5月签订谅解备忘录，此后首只主动型ETF于7月在香港互挂上市，其投资于爱尔兰的主 ETF。此外，香港证监会与沙特阿拉伯资本市场管理局于6月在香港进行双边会议，以加强双方的联 系，并合办了圆桌会议，让资产管理公司探讨合作机会。 为了便利特专科技公司及生物科技公司上市，香港证监会与香港联合交易所有限公司于5月联合宣布推 出"科企专线"，并提供以保密形式提交上市申请的选择。 香港证券市场于4月初面对极端波动市况时亦展现出一贯的韧力，维持了有序正常运作。此后，恒生指 数强劲反弹，达到三年多以来的高位，而首七个月市场的日均成交额亦跃升85%至 2,437亿港元。 在第二季，香港证监会收到的牌照申请数目按年增加16%，亦印证市场蓬勃发展。此外，资产及财富管 理业在季内录得强劲增长，在香港注册成立的基金的管理资产按年稳健增长39%，其中货币市场基金持 续录得资金流入。开放式基金型公司数目按年大增56%，而香港证监会认可交易所买卖基金(exchange- traded fund，简称ETF)的日均成交额于季内按年飙升13 ...

Core Viewpoint - Nanjing Weilizhi Bio-Technology Co., Ltd. announced the results of its global offering, with significant oversubscription in the Hong Kong public offering and a planned listing on the Hong Kong Stock Exchange on July 25, 2025 [1][2]. Group 1: Offering Details - The Hong Kong public offering was oversubscribed by 3,494.78 times, while the international offering had a subscription rate of 40.78 times [1][2]. - The final issue price was set at HKD 35.00 per share, at the upper limit of the price range of HKD 31.60 to HKD 35.00 [1]. - The total number of shares issued was 36,862,500 H-shares, with 16,027,200 shares allocated for the Hong Kong offering and 20,835,300 shares for the international offering [1]. Group 2: Fundraising and Allocation - The total amount raised, after accounting for estimated listing expenses of HKD 110 million, was HKD 1.18 billion [1]. - A total of 12,821,700 shares were reallocated from the international offering to the Hong Kong public offering due to the oversubscription, resulting in 43.48% of shares allocated to the Hong Kong offering and 56.52% to the international offering [2]. - Seventeen cornerstone investors participated, receiving a total of 15,474,500 shares, which accounted for 41.98% of the offering shares and 8.00% of the total shares post-offering [2].

Core Viewpoint - The initial public offering (IPO) of Bokan Vision Pharmaceutical Co., Ltd. (02592.HK) on the Hong Kong Stock Exchange faced a significant decline, with shares opening at HKD 9.50 and closing at HKD 6.20, representing a drop of 38.61% [1] Group 1: Company Overview - Bokan Vision is a clinical-stage ophthalmic biotechnology company focused on developing various therapies, with its core product being CBT-009, an atropine eye preparation for treating myopia in adolescents [1] - The total number of shares issued at the time of listing was 838,892,874 [2] Group 2: IPO Details - The final offer price for the shares was HKD 10.10, raising a total of HKD 611.88 million, with a net amount of HKD 522.21 million after deducting estimated listing expenses of HKD 89.67 million [2] - The number of shares offered was 60,582,000, with 12,115,500 shares allocated for public offering in Hong Kong and 48,466,500 shares for international offering [2] Group 3: Use of Proceeds - The net proceeds from the global offering are intended for ongoing clinical research and development activities for core products CBT-001 and CBT-009, as well as funding for production facilities, commercialization activities, and general corporate purposes [2] Group 4: Financial Performance - Bokan Vision has not recorded any revenue and has faced significant business failure risks, with net losses of USD 66.84 million, USD 129.42 million, and USD 99.13 million for the years 2022 to 2024, totaling USD 295.39 million [5] - Research and development expenditures for the years 2022, 2023, and 2024 were USD 15.3 million, USD 27.5 million, and USD 37.9 million, respectively [5] - The net cash used in operating activities for the same years was USD 20.05 million, USD 22.51 million, and USD 26.52 million [6][7]

Core Viewpoint - The Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange have launched a "Specialized Technology Company Line" to facilitate the listing of specialized technology and biotechnology companies, allowing them to submit listing applications confidentially [2][3]. Group 1: Introduction of the Specialized Technology Company Line - The "Specialized Technology Company Line" aims to help specialized technology and biotechnology companies understand the applicable listing rules and prepare for listing before submitting formal applications [2]. - A professional team with relevant experience will lead the initiative, and the Hong Kong Stock Exchange will engage with potential applicants to better understand their business and provide guidance on listing qualifications and suitability [2]. Group 2: Confidential Application Process - Companies in early development stages or with non-commercialized products may face high risks from premature disclosure of operational strategies, proprietary technologies, or listing plans [2]. - To mitigate these risks, the Hong Kong Stock Exchange will allow companies to submit applications confidentially under specific chapters of the Main Board Listing Rules [2]. Group 3: Compliance with Listing Rules - Specialized technology companies that fully comply with Chapter 18C of the Main Board Listing Rules and biotechnology companies that comply with Chapter 18A will be recognized as meeting the criteria for innovative industry companies [3].

Core Viewpoint - The launch of the "Tech Company Fast Track" aims to facilitate the listing process for specialized technology and biotechnology companies in Hong Kong, allowing them to submit applications confidentially [1][2][3]. Group 1: Introduction of the "Tech Company Fast Track" - The Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange announced the "Tech Company Fast Track" to ease the listing process for specialized technology and biotechnology firms [1]. - The initiative is designed to help these companies better understand the listing rules and prepare for their applications [2]. Group 2: Measures Provided by the Fast Track - The Hong Kong Stock Exchange will implement three main measures to assist potential applicants, including guidance on listing qualifications and suitability [2]. - Companies can submit their applications confidentially to protect sensitive operational strategies and proprietary technologies during early development stages [2][3]. Group 3: Support from Regulatory Authorities - The initiative is supported by the Hong Kong Securities and Futures Commission, which aims to solidify Hong Kong's position as a preferred listing platform for emerging and innovative companies [3]. - The Hong Kong Stock Exchange emphasizes the importance of regulatory transparency and aims to enhance the market's vitality and competitiveness through this initiative [3]. Group 4: Broader Economic Initiatives - The Chief Executive of Hong Kong, John Lee, announced plans to visit Qatar and Kuwait to assist specialized technology and biotechnology companies in financing and business development [4]. - The visit aims to strengthen international cooperation and showcase Hong Kong's role as a bridge for businesses [4]. Group 5: Recent Developments in Zhejiang - The Chief Executive recently concluded a visit to Zhejiang, resulting in the establishment of a cooperation mechanism and the signing of four cooperation documents in various sectors [6][7]. - The visit also opened new opportunities for collaboration in technology innovation and encouraged Zhejiang enterprises to invest in Hong Kong [7].

Core Viewpoint - The Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange have launched a "Tech Company Fast Track" to facilitate the listing of specialized technology and biotechnology companies, allowing them to submit applications confidentially [1][5]. Group 1: Purpose and Functionality - The "Tech Company Fast Track" aims to assist specialized technology and biotechnology companies in understanding listing rules and preparing for their applications before submission [3][4]. - A professional team with relevant experience will lead the initiative, providing guidance on the Hong Kong Listing Rules and engaging with potential applicants to understand their business [3][4]. - The program will offer guidance on listing qualifications, including core product requirements and the acceptance of clinical trials regulated by different authorities [3][5]. Group 2: Confidentiality and Risk Mitigation - Companies in early development stages may face risks from premature disclosure of operational strategies or proprietary technologies; thus, the fast track allows for confidential submission of applications [5][6]. - The initiative supports companies seeking to list with different voting rights structures, ensuring compliance with relevant regulations [5][6]. Group 3: Regulatory Support and Market Position - The Hong Kong Stock Exchange aims to enhance regulatory transparency and support the development of innovative enterprises, thereby boosting market vitality and competitiveness [5]. - The establishment of the "Tech Company Fast Track" reinforces Hong Kong's position as a preferred listing platform for emerging and innovative companies [5][6].

Group 1 - The Hong Kong Securities and Futures Commission (SFC) and the Hong Kong Stock Exchange (HKEX) launched the "Tech Company Fast Track" to facilitate the listing of specialized technology and biotech companies, allowing them to submit applications confidentially [10][11]. - The Hang Seng Index rose by 0.7% to 22,662.71 points, while the Hang Seng Tech Index fell by 0.09% to 5,239.5 points, with a total market turnover of HKD 213.368 billion [2]. - Macau's gaming revenue for April 2025 was MOP 18.85 billion, showing a year-on-year increase of 1.7% but a month-on-month decrease of 4.07% [4]. Group 2 - Major airline stocks surged during the "May Day" holiday, with China Eastern Airlines rising by 7.3% and China Southern Airlines by 6.56% [5]. - The number of visitors entering Macau from May 1 to May 5 reached 3.754 million, averaging 170,000 daily, with the majority entering through the Gongbei Port [3]. - CATL (Contemporary Amperex Technology Co., Limited) is preparing for its listing in Hong Kong, with significant projects underway in Hungary, Spain, and Indonesia, and holds a 36.5% market share in global energy storage battery shipments by 2024 [7][10].

Core Viewpoint - The Hong Kong Securities and Futures Commission (SFC) and the Hong Kong Stock Exchange (HKEX) have launched a "Tech Company Fast Track" to facilitate the listing of specialized technology and biotechnology companies, allowing them to submit applications confidentially [1][2] Group 1: Announcement Details - The HKEX will permit specialized technology and biotechnology companies to submit listing applications in a confidential manner [1] - The HKEX has updated the "New Listing Applicants Guide" to clarify that these companies will be considered compliant with the innovative industry and external recognition requirements under Chapter 8A of the Main Board Listing Rules when adopting different voting rights structures [1] Group 2: Objectives and Support - The initiative aims to provide specialized guidance to technology and biotechnology companies during the early stages of their listing preparations, helping them understand and meet relevant listing requirements [1] - The HKEX seeks to enhance regulatory transparency, support the development of innovative enterprises, and boost the vitality, competitiveness, and resilience of the Hong Kong market [1] Group 3: Regulatory Perspective - The SFC supports the establishment of the "Tech Company Fast Track" and the option for specialized technology and biotechnology companies to submit applications confidentially, reinforcing Hong Kong's position as a preferred listing platform for emerging and innovative companies [2] - The SFC emphasizes the importance of adapting the listing system to global market changes while ensuring robust investor protection [2] - The option for confidential submissions is particularly relevant for companies in early development stages or those with non-commercialized products, as premature disclosure of operational strategies or proprietary technologies could pose significant risks [2]

Core Viewpoint - The launch of the "Tech Company Fast Track" aims to facilitate the listing process for specialized technology and biotech companies in Hong Kong, allowing them to submit applications confidentially, which exceeds market expectations [1][2][7]. Group 1: Announcement Details - On May 6, the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange announced the official launch of the "Tech Company Fast Track" [1]. - The initiative was first announced by the Financial Secretary of Hong Kong on February 26, aimed at assisting specialized technology and biotech companies in their fundraising and listing processes [4]. - The updated "New Listing Applicant Guide" will help these companies understand the listing requirements and regulations [1]. Group 2: Objectives and Benefits - The "Tech Company Fast Track" is designed to attract high-quality companies to list in Hong Kong, providing tailored guidance to potential issuers [5]. - It aims to enhance regulatory transparency and support the development of innovative enterprises, thereby boosting the competitiveness and resilience of the Hong Kong market [5]. - The initiative reflects the commitment of the Hong Kong Stock Exchange to adapt to global market changes while ensuring investor protection [5]. Group 3: Key Features - The program includes a professional team to assist companies in understanding the listing rules and preparing for their applications [8]. - Companies can now submit their applications confidentially, which is crucial for those in early development stages to mitigate risks associated with premature disclosure [9]. - The program clarifies regulations for companies seeking to list with different voting rights structures, ensuring compliance with relevant listing rules [10][11].